Enteric Empty Capsules Market Size & Growth Forecast 2027–2036, By Segments (Product, Application, End-use), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growth Outlook
Enteric Empty Capsules Market size was around USD 3.5 billion in 2026 and is slated to grow at a 6.08% CAGR from 2027 to 2036, reaching USD 6.32 billion by 2036. The industry revenue for 2027 is assessed at USD 3.68 billion.
Get more details on this report
Request Free Sample ReportEnteric Empty Capsules Market Intelligence Snapshot
Regional Market Dynamics
- North America accounted for 45.30% of the market in 2026, driven by its established pharmaceutical and nutraceutical manufacturing base, advanced formulation capabilities, and strong use of targeted oral delivery systems.
- Asia Pacific is expected to expand at a 7.46% CAGR as pharmaceutical and nutraceutical production grows, increasing demand for specialized capsule technologies for domestic and export-oriented formulations.
Segment Momentum
- Gelatin capsules accounted for 59.37% of the market in 2026 due to their manufacturing familiarity, cost-efficient production, proven processing compatibility, and reliable integration into pharmaceutical filling and coating operations.
- HPMC capsules are expanding rapidly because they support evolving formulation needs with greater material flexibility and non-animal-derived options, making them increasingly attractive for specialized pharmaceutical product development.
Market Expansion Drivers
- Rising demand for pharmaceutical drug delivery systems driving adoption of acid-resistant enteric capsules.
- Increasing prevalence of gastrointestinal disorders boosting need for targeted intestinal drug release solutions.
- Advancements in capsule coating technologies improving drug stability and expanding pharmaceutical formulation applications.
Leading Market Participants
- Key players in the enteric empty capsules market include Lonza Group AG (Switzerland), Roquette Frères S.A. (France), Suheung Co., Ltd. (South Korea), Farmacapsulas S.A. (Colombia), Nectar Lifesciences Limited (India), Zhejiang Huili Capsules Co., Ltd. (China), Shaoxing Zhongya Capsule Co., Ltd. (China), Chemcaps Limited (India), Natural Capsules Limited (India), ACG Worldwide (India).
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 3.5 billion
- 2027 Estimated Market Size: USD 3.68 billion.
- Projected Market Size: USD 6.32 billion by 2036
- Growth Forecast: 6.08% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Gelatin Capsules (Product) | Antibiotic and Antibacterial Drugs (Application) | Pharmaceutical Manufacturers (End-use)
- Emerging Opportunity Segment: Hydroxypropyl Methylcellulose (HPMC) Capsules (Product) | Antibiotic and Antibacterial Drugs (Application) | Nutraceutical Manufacturers (End-use)
Market Growth Drivers and Industry Trends
Rising demand for pharmaceutical drug delivery systems driving adoption of acid-resistant enteric capsules
The expanding need for specialized pharmaceutical delivery systems is supporting the enteric empty capsules market as drug manufacturers seek dosage forms capable of protecting active ingredients from degradation in acidic stomach conditions. Acid-resistant capsules can delay drug release until the formulation reaches the intended intestinal environment, making them suitable for active ingredients that require protection or controlled site-specific delivery. Their application in pharmaceutical formulations also provides flexibility for developing oral dosage forms with improved release characteristics, particularly when conventional capsule systems are unsuitable for the stability or absorption requirements of a drug.
Increasing prevalence of gastrointestinal disorders boosting need for targeted intestinal drug release solutions
A rising burden of gastrointestinal disorders is increasing the need for formulations that can deliver therapeutic ingredients closer to the affected region of the digestive tract, thereby supporting the enteric empty capsules market. Enteric delivery systems can help prevent premature release in the stomach and facilitate drug availability within the intestine, which is particularly valuable for therapies where localized or ph-dependent release is important. The ability to incorporate such delivery characteristics into oral dosage forms is encouraging pharmaceutical developers to consider enteric capsules for treatments addressing a range of gastrointestinal conditions.
Advancements in capsule coating technologies improving drug stability and expanding pharmaceutical formulation applications
Progress in capsule coating technologies is improving the protective characteristics and functional performance of enteric dosage forms, contributing to the enteric empty capsules market. Enhanced coating approaches can provide greater resistance to gastric conditions while allowing controlled dissolution under the appropriate intestinal environment. Improvements in coating consistency, formulation compatibility, and protection of sensitive active ingredients are also enabling pharmaceutical developers to explore enteric capsule formats across a broader range of formulations, including products where stability and release control are important considerations.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Rising demand for pharmaceutical drug delivery systems driving adoption of acid-resistant enteric capsules | 2.00% | High | North America, Europe | High | Near Term |
| Increasing prevalence of gastrointestinal disorders boosting need for targeted intestinal drug release solutions | 1.80% | High | North America, Asia Pacific | High | Near Term |
| Advancements in capsule coating technologies improving drug stability and expanding pharmaceutical formulation applications | 1.50% | Moderate | Europe, Asia Pacific | Medium | Mid Term |
Explore Growth Opportunities
Request Free Sample ReportRegional Demand Dynamics
North America (Largest Region)
The enteric empty capsules market was led by North America, which held a 45.30% share in 2026, supported by a mature pharmaceutical industry, sophisticated drug formulation capabilities, and established demand for specialized oral dosage forms. Enteric capsules are increasingly important for formulations requiring protection from gastric conditions and controlled release within the gastrointestinal tract. Strong pharmaceutical manufacturing infrastructure, emphasis on advanced drug delivery, and demand for patient-oriented dosage technologies continue to support regional market development.
Asia Pacific (Fastest-Growing Region)
Asia Pacific is experiencing the fastest growth, driven by expanding pharmaceutical manufacturing capacity, increasing healthcare access, and rising demand for advanced oral drug delivery systems. Growing production of generic and specialty medicines is creating additional opportunities for specialized capsule technologies, while improvements in pharmaceutical infrastructure are facilitating wider adoption. Increasing investment in drug formulation capabilities and the modernization of healthcare systems are expected to further strengthen demand across the region.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
GMP capsule specializationIn Germany, enteric empty capsules are primarily driven by stringent GMP compliance requirements and advanced pharmaceutical manufacturing standards, with manufacturers focusing on high-precision capsule engineering for controlled release formulations. Demand is reinforced by established pharmaceutical production clusters emphasizing quality assurance and regulatory adherence.
France 🇫🇷
Pharmaceutical grade customizationIn France, enteric empty capsules are shaped by pharmaceutical-grade customization needs within hospital and specialty pharmacy environments, where tailored drug delivery solutions are used to improve therapeutic outcomes. French manufacturers emphasize flexible capsule formulation capabilities aligned with clinical prescription requirements.
Italy 🇮🇹
Manufacturing efficiency upgradesIn Italy, enteric empty capsules production is influenced by ongoing manufacturing efficiency upgrades within pharmaceutical facilities, with emphasis on improving process consistency and reducing production variability. Italian manufacturers focus on optimizing capsule filling operations to support cost-effective delivery of enteric-coated formulations across therapeutic segments.
Japan 🇯🇵
Controlled-release demand focusIn Japan, enteric empty capsules demand is influenced by strong requirements for controlled-release drug delivery systems tailored to an aging population and chronic disease management. Pharmaceutical and nutraceutical developers in Japan prioritize capsule technologies that ensure precise gastrointestinal targeting and improved patient compliance.
South Korea 🇰🇷
Nutraceutical capsule growthIn South Korea, enteric empty capsules are increasingly utilized in the nutraceutical and dietary supplement sector, where consumer demand for functional health products drives innovation in capsule design and formulation. Manufacturers focus on enhancing bioavailability and taste-masking capabilities for premium supplement offerings.
United States 🇺🇸
Pharma formulation outsourcingIn the United States, enteric empty capsules demand is strongly tied to pharmaceutical formulation outsourcing and nutraceutical product development, with manufacturers relying on specialized capsule technologies to support delayed-release and targeted delivery systems. Contract manufacturing partnerships drive customization across drug and supplement applications.
Segment Leadership and Growth Trends
Enteric Empty Capsules Market Share (%), by Product, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportProduct Segment Analysis: Gelatin Capsules (Largest Segment) vs Hydroxypropyl Methylcellulose (HPMC) Capsules (Fastest-Growing Segment)
Gelatin capsules led the enteric empty capsules market with a 59.37% share in 2026, supported by their established use in pharmaceutical formulations, compatibility with a broad range of active ingredients, and well-developed manufacturing and supply infrastructure. Their widespread acceptance among pharmaceutical manufacturers is reinforced by consistent performance, formulation familiarity, and established production processes. Demand for enteric delivery formats also benefits from the need to protect acid-sensitive ingredients and support targeted release within the gastrointestinal tract, sustaining the position of gelatin capsules across conventional pharmaceutical applications.
Hydroxypropyl methylcellulose (HPMC) capsules represent the fastest-growing product segment, driven by increasing interest in plant-derived capsule materials and formulation flexibility. Their adoption is supported by growing preference for non-animal-based alternatives, particularly among manufacturers seeking broader product positioning and compatibility with changing consumer expectations. HPMC capsules also offer advantages for specialized formulations and can support pharmaceutical development strategies where material characteristics, stability, and dosage-form differentiation are important considerations.
Application Segment Analysis: Antibiotic and Antibacterial Drugs (Largest & Fastest-Growing Segment)
In the enteric empty capsules market, antibiotic and antibacterial drugs accounted for a 48.61% share in 2026 and represented both the largest and fastest-growing application segment. The segment's strong position reflects continued demand for dosage forms that can protect active pharmaceutical ingredients from unfavorable gastric conditions and facilitate appropriate drug release in the gastrointestinal tract. Increasing emphasis on effective oral drug delivery, formulation stability, and targeted release supports the use of enteric capsules in antibiotic and antibacterial therapies. Pharmaceutical manufacturers' focus on improving formulation performance and maintaining drug efficacy further strengthens demand within this application area.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Product | Gelatin Capsules, Hydroxypropyl Methylcellulose (HPMC) Capsules, Vegetable Capsules | Gelatin Capsules | Hydroxypropyl Methylcellulose (HPMC) Capsules |
| Application | Antacid and Antiflatulent Preparations, Antibiotic and Antibacterial Drugs, Others | Antibiotic and Antibacterial Drugs | Antibiotic and Antibacterial Drugs |
| End-use | Pharmaceutical Manufacturers, Nutraceutical Manufacturers, Others | Pharmaceutical Manufacturers | Nutraceutical Manufacturers |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Competitive Landscape and Market Positioning
Top players in the enteric empty capsules market:
1. Lonza Group AG (Switzerland)
2. Roquette Frères S.A. (France)
3. Suheung Co. Ltd. (South Korea)
4. Farmacapsulas S.A. (Colombia)
5. Nectar Lifesciences Limited (India)
6. Zhejiang Huili Capsules Co. Ltd. (China)
7. Shaoxing Zhongya Capsule Co. Ltd. (China)
8. Chemcaps Limited (India)
9. Natural Capsules Limited (India)
10. ACG Worldwide (India)
Demand for targeted drug delivery systems is shaping the enteric empty capsules market. Improvements in capsule stability and dissolution control are enhancing pharmaceutical performance. In the enteric empty capsules market, formulation innovation is strengthening delivery precision and patient compatibility.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| Lonza Group AG (Switzerland) | |||||||
| Roquette Frères S.A. (France) | |||||||
| Suheung Co. Ltd. (South Korea) | |||||||
| Farmacapsulas S.A. (Colombia) | |||||||
| Nectar Lifesciences Limited (India) | |||||||
| Zhejiang Huili Capsules Co. Ltd. (China) | |||||||
| Shaoxing Zhongya Capsule Co. Ltd. (China) | |||||||
| Chemcaps Limited (India) | |||||||
| Natural Capsules Limited (India) | |||||||
| ACG Worldwide (India). |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| ACG | May-25 | ACG introduced a personalized capsule machine (PCM) enabling on-demand capsule formulation, expanding its capabilities into personalized drug delivery and nutrition solutions. In collaboration with Art of You, the initiative strengthens ACG’s position in customized capsule manufacturing and next-generation oral dosage innovation. |
| Lonza Group Ltd. | Jun-24 | Lonza Group introduced Capsugel Enprotect in a size 9 format designed to protect acid-sensitive active pharmaceutical ingredients from stomach acid and enable enteric release in the intestine. The solution is primarily targeted at pre-clinical rodent studies, aiming to improve early-stage drug evaluation efficiency and accelerate development timelines in pharmaceutical research workflows. |
| ACG Worldwide | Dec-23 | ACG Worldwide’s capsule manufacturing facility in Pithampur, India was recognized under the World Economic Forum’s Global Lighthouse Network. The recognition highlights the facility’s adoption of advanced manufacturing technologies that significantly enhance operational efficiency and digital transformation in pharmaceutical capsule production. |
| Evonik | Oct-23 | Evonik launched the EUDRACAP functional oral capsule platform, including a size 9h enteric-coated capsule designed for preclinical studies. The solution supports smoother transition from preclinical to first-in-human trials by improving drug stability for acid-sensitive compounds and reducing development risk and complexity for pharmaceutical developers. |
| Lonza | Nov-22 | Lonza launched Capsugel Enprotect capsules designed for enteric delivery of acid-sensitive active pharmaceutical ingredients, ensuring release in the intestine rather than the stomach. The development strengthened Lonza’s capsule technology portfolio and supported improved formulation stability in pharmaceutical manufacturing. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Enteric Empty Capsules Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Release Profile | Delayed-Release Capsules, Extended-Release Capsules, Pulsatile-Release Capsules |
| Dosage Form | Immediate-Release Oral Dosage Forms, Modified-Release Oral Dosage Forms, Combination & Fixed-Dose Oral Forms |
| Manufacturing & Procurement Model | In-house Manufacturing, Contract Manufacturing, Hybrid Manufacturing & Procurement |
Enteric Empty Capsules Market — Custom TOC
| Custom Chapter | Chapter Details |
|---|---|
| Pharmaceutical Formulation Application Analysis |
|
| Drug Delivery Innovation Opportunities |
|
| Nutraceutical Adoption Opportunity Study |
|
Need a different cut of the data?
Request Custom ResearchHow large is the enteric empty capsules market?
How will the enteric empty capsules industry grow in terms of size and CAGR by 2036?
How are pharmaceutical formulation priorities driving adoption of enteric empty capsules?
What technology trends are expanding the application potential of enteric empty capsules?
Why do gelatin capsules lead the enteric empty capsules market?
Why are Hydroxypropyl Methylcellulose (HPMC) capsules the fastest-growing product segment?
Why is North America the largest market for enteric empty capsules?
What factors are supporting enteric empty capsule market growth in Asia Pacific?
Who holds a significant market share in the enteric empty capsules landscape?
Our Clients
"The team took the time to understand our specific business needs and delivered a report that was well aligned with our objectives. Their expertise and understanding of the industry were clearly reflected in the quality and relevance of the insights provided."
Siemens Healthcare
"Our experience in acquiring the research report has been excellent. The depth of analysis, and actionable insights provided have been extremely valuable in supporting our ongoing R&D efforts."
GC Biopharma
"The report offered a comprehensive view of the market trends. The in-depth segmentation and analysis of emerging opportunities gave us a better understanding of the market."
Medtronic
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Intelligence
| Source | Reference |
|---|---|
| World Health Organization (WHO) | www.who.int |
| U.S. Food & Drug Administration (FDA) | www.fda.gov |
| European Medicines Agency (EMA) | www.ema.europa.eu |
| Centers for Disease Control and Prevention (CDC) | www.cdc.gov |
| National Institutes of Health (NIH) | www.nih.gov |
| National Center for Biotechnology Information (NCBI) | www.ncbi.nlm.nih.gov |
| PubMed | pubmed.ncbi.nlm.nih.gov |
| ClinicalTrials.gov | clinicaltrials.gov |
| International Organization for Standardization (ISO) | www.iso.org |
| ASTM International | www.astm.org |
| Advanced Medical Technology Association (AdvaMed) | www.advamed.org |
| Medical Device Innovation Consortium (MDIC) | mdic.org |
| Biotechnology Innovation Organization (BIO) | www.bio.org |
| International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) | www.ifpma.org |
| U.S. Pharmacopeia (USP) | www.usp.org |
| European Directorate for the Quality of Medicines & HealthCare (EDQM) | www.edqm.eu |
| World Organisation for Animal Health (WOAH) | www.woah.org |
| American Hospital Association (AHA) | www.aha.org |
| OECD Health | www.oecd.org/health |
| World Bank Data | data.worldbank.org |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization